Back to Search
Start Over
A Phase II, Single-Arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma
- Source :
- Clinical Genitourinary Cancer; 20220101, Issue: Preprints
- Publication Year :
- 2022
-
Abstract
- : Overexpression of the epidermal growth factor receptor (EGFR) and its ligands occur frequently in renal cell carcinoma (RCC). Combined vascular endothelial growth factor receptor (VEGF-R) and EGFR inhibition may overcome resistance to VEGF-R inhibitor monotherapy. We performed a dose-escalation phase II study of sunitinib plus erlotinib in advanced renal cell carcinoma.
Details
- Language :
- English
- ISSN :
- 15587673
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Clinical Genitourinary Cancer
- Publication Type :
- Periodical
- Accession number :
- ejs59621729
- Full Text :
- https://doi.org/10.1016/j.clgc.2022.04.018